<DOC>
	<DOCNO>NCT00885547</DOCNO>
	<brief_summary>The purpose study : 1 . To evaluate late effect TW IgA nephropathy ( IgAN ) asymptomatic abnormal urinalysis . 2 . To evaluate safety tolerability TW .</brief_summary>
	<brief_title>Prospective Study TW Treatment IgAN With Asymptomatic Abnormal Urinalysis</brief_title>
	<detailed_description>Patients fit inclusion criterion randomly divide three group : TW group ( TW dosage 90 mg/d ) , ARB group ( control group , valsartan dosage 160 mg/d ) combine treatment group ( TW dosage 60 mg/d valsartan dosage 80 mg/d ) .</detailed_description>
	<mesh_term>Glomerulonephritis , IGA</mesh_term>
	<criteria>1 . 1860 year old requirement gender 2 . All well fit Diagnostic Criteria Primary IgAN IgAN asymptomatic abnormal urinalysis 3 . Informed consent obtain research subject agree conduct periodic followup accord research arrangement 1 . Secondary IgA nephropathy , HenochSch√∂nlein purpura nephritis , Lupus nephritis 2 . Some secondary kidney disease like diabetic nephropathy systemic disease may effect pathologic physiological function kidney like hypertension arteriosclerosis 3 . Severe infection 4 . Abnormality liver function glutamic pyruvic transaminase ( GPT ) glutamicoxal ( ) acetic transaminase ( GOT ) twice upper limit normal 5 . Women pregnancy lactation 6 . Patients need procreation lately 7 . Patients treat TW ARB within 4 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>